Hypertension Canada's 2017 Guidelines for the Diagnosis, Assessment, Prevention, and Treatment of Pediatric Hypertension

Canadian Journal of Cardiology

Volumn 33, Issue 5, 2017, Pages 577-585

  Dionne, Janis M ^a   Harris, Kevin C ^a   Benoit, Geneviève ^b   Feber, Janusz ^c   Poirier, Luc ^d   Cloutier, Lyne ^e   Nakhla, Meranda ^f   Rabi, Doreen M ^g   Daskalopoulou, Stella S ^h   Fournier, Anne ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

^c CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^d LAVAL UNIVERSITY   (Canada)

^e UNIVERSITÉ DU QUÉBEC À TROIS RIVIÈRES   (Canada)

^f MONTREAL CHILDREN S HOSPITAL   (Canada)

^g UNIVERSITY OF CALGARY   (Canada)

^h MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; BLOOD PRESSURE MONITORING; CANADA; CARDIOVASCULAR RISK; CHILD; CLINICAL ASSESSMENT; ECHOCARDIOGRAPHY; HEALTH BEHAVIOR; HUMAN; HYPERTENSION; LABORATORY TEST; LIFESTYLE MODIFICATION; PEDIATRICS; PRACTICE GUIDELINE; RISK ASSESSMENT; TREATMENT INDICATION; ADOLESCENT; BEHAVIOR CONTROL; BLOOD PRESSURE MEASUREMENT; CLASSIFICATION; DISEASE MANAGEMENT; EPIDEMIOLOGY; LIFESTYLE; PROCEDURES; PSYCHOLOGY; RISK REDUCTION; STANDARDS;

ADOLESCENT; ANTIHYPERTENSIVE AGENTS; BEHAVIOR CONTROL; BLOOD PRESSURE DETERMINATION; CANADA; CHILD; DISEASE MANAGEMENT; HUMANS; HYPERTENSION; LIFE STYLE; RISK ASSESSMENT; RISK REDUCTION BEHAVIOR;

EID: 85018707859     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2017.03.007     Document Type: Article

References (49)

1. 1 Shi, Y., Groh, M., Morrison, H., Increasing blood pressure and its associated factors in Canadian children and adolescents from the Canadian Health Measures Survey. BMC Public Health, 12, 2012, 388.
2. 2 Statistics Canada. Blood pressure of children and youth, 2012 to 2013. Available at: www.statcan.gc.ca/pub/82-625-x/2014001/article/14102-eng.htm Accessed December 7, 2016.
3. 3 Yang, Q., Zhong, Y., Merritt, R., Cogswell, M.E., Trends in high blood pressure among United States adolescents across body weight category between 1988 and 2012. J Pediatr 169 (2016), 166–173.
4. 4 Harris, K.C., Benoit, G., Dionne, J., et al. Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for blood pressure measurement, diagnosis, and assessment of risk of pediatric hypertension. Can J Cardiol 32 (2016), 589–597.
5. 5 McAlister, F.A., The Canadian Hypertension Education Program – a unique Canadian initiative. Can J Cardiol 22 (2006), 559–564.
6. 6 Brouwers, M.C., Kho, M.E., Browman, G.P., et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ 182 (2010), E839–E842.
7. 7 Rosner, B., Cook, N.R., Daniels, S., Falkner, B., Childhood blood pressure trends and risk factors for high blood pressure: the NHANES experience 1988-2008. Hypertension 62 (2013), 247–254.
8. 8 Yang, Q., Zhang, Z., Kuklina, E.V., et al. Sodium intake and blood pressure among us children and adolescents. Pediatrics 130 (2012), 611–619.
9. 9 Colin-Ramirez, E., Castillo-Martinez, L., Orea-Tejeda, A., et al. Waist circumference and fat intake are associated with high blood pressure in Mexican children aged 8 to 10 years. J Am Diet Assoc 109 (2009), 996–1003.
10. 10 Lobelo, F., Pate, R.R., Dowda, M., Liese, A.D., Daniels, S.R., Cardiorespiratory fitness and clustered cardiovascular disease risk in U.S. adolescents. J Adolesc Health 47 (2010), 352–359.
11. 11 Farpour-Lambert, N.J., Aggoun, Y., Marchand, L.M., et al. Physical activity reduces systemic blood pressure and improves early markers of atherosclerosis in pre-pubertal obese children. J Am Coll Cardiol 54 (2009), 2396–2406.
12. 12 Garcia-Hermoso, A., Saavedra, J.M., Escalante, Y., Effects of exercise on resting blood pressure in obese children: a meta-analysis of randomized controlled trials. Obes Rev 14 (2013), 919–928.
13. 13 He, F.J., MacGregor, G.A., Importance of salt in determining blood pressure in children: meta-analysis of controlled trials. Hypertension 48 (2006), 861–869.
14. 14 Buendia, J.R., Bradlee, M.L., Daniels, S.R., Singer, M.R., Moore, L.L., Longitudinal effects of dietary sodium and potassium on blood pressure in adolescent girls. JAMA Pediatr 169 (2015), 560–568.
15. 15 Saneei, P., Hashemipour, M., Kelishadi, R., Rajaei, S., Esmaillzadeh, A., Effects of recommendations to follow the Dietary Approaches to Stop Hypertension (DASH) diet vs. usual dietary advice on childhood metabolic syndrome: a randomised cross-over clinical trial. Br J Nutr 110 (2013), 2250–2259.
16. 16 Cai, L., Wu, Y., Wilson, R.F., et al. Effect of childhood obesity prevention programs on blood pressure: a systematic review and meta-analysis. Circulation 129 (2014), 1832–1839.
17. 17 Schwandt, P., Bertsch, T., Haas, G.M., Sustained lifestyle advice and cardiovascular risk factors in 687 biological child-parent pairs: the PEP Family Heart Study. Atherosclerosis 219 (2011), 937–945.
18. 18 Sladowska-Kozlowska, J., Litwin, M., Niemirska, A., et al. Change in left ventricular geometry during antihypertensive treatment in children with primary hypertension. Pediatr Nephrol 26 (2011), 2201–2209.
19. 19 Assadi, F., Effect of microalbuminuria lowering on regression of left ventricular hypertrophy in children and adolescents with essential hypertension. Pediatr Cardiol 28 (2007), 27–33.
20. 20 Kupferman, J.C., Paterno, K., Mahgerefteh, J., et al. Improvement of left ventricular mass with antihypertensive therapy in children with hypertension. Pediatr Nephrol 25 (2010), 1513–1518.
21. 21 Matteucci, M.C., Chinali, M., Rinelli, G., et al. Change in cardiac geometry and function in CKD children during strict BP control: a randomized study. Clin J Am Soc Nephrol 8 (2013), 203–210.
22. 22 National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. Pediatrics 114:suppl 2 (2004), 555–576.
23. 23 Meyers, R.S., Siu, A., Pharmacotherapy review of chronic pediatric hypertension. Clin Ther 33 (2011), 1331–1356.
24. 24 Wells, T., Frame, V., Soffer, B., et al. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension. J Clin Pharmacol 42 (2002), 870–880.
25. 25 Soffer, B., Zhang, Z., Miller, K., et al. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. Am J Hypertens 16 (2003), 795–800.
26. 26 Li, J.S., Berezny, K., Kilaru, R., et al. Is the extrapolated adult dose of fosinopril safe and effective in treating hypertensive children?. Hypertension 44 (2004), 289–293.
27. 27 Li, J.S., Baker-Smith, C.M., Smith, P.B., et al. Racial differences in blood pressure response to angiotensin-converting enzyme inhibitors in children: a meta-analysis. Clin Pharmacol Ther 84 (2008), 315–319.
28. 28 Chu, P.Y., Campbell, M.J., Miller, S.G., Hill, K.D., Anti-hypertensive drugs in children and adolescents. World J Cardiol 6 (2014), 234–244.
29. 29 Baker-Smith, C.M., Benjamin, D.K., Califf, R.M., et al. Cough in pediatric patients receiving angiotensin-converting enzyme inhibitor therapy or angiotensin receptor blocker therapy in randomized controlled trials. Clin Pharmacol Ther 87 (2010), 668–671.
30. 30 Shahinfar, S., Cano, F., Soffer, B., et al. A double-blind, dose-response study of losartan in hypertensive children. Am J Hypertens 18 (2005), 183–190.
31. 31 Trachtman, H., Hainer, J.W., Sugg, J., et al. Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. J Clin Hypertens (Greenwich) 10 (2008), 743–750.
32. 32 Hazan, L., Hernandez Rodriguez, O.A., Bhorat, A.E., et al. A double-blind, dose-response study of the efficacy and safety of olmesartan medoxomil in children and adolescents with hypertension. Hypertension 55 (2010), 1323–1330.
33. 33 Wells, T., Blumer, J., Meyers, K.E., et al. Effectiveness and safety of valsartan in children aged 6 to 16 years with hypertension. J Clin Hypertens 13 (2011), 357–365.
34. 34 Schaefer, F., Litwin, M., Zachwieja, J., et al. Efficacy and safety of valsartan compared to enalapril in hypertensive children: a 12-week, randomized, double-blind, parallel-group study. J Hypertens 29 (2011), 2484–2490.
35. 35 Batisky, D.L., Sorof, J.M., Sugg, J., et al. Efficacy and safety of extended release metoprolol succinate in hypertensive children 6 to 16 years of age: a clinical trial experience. J Pediatr 150 (2007), 134–139.
36. 36 Poirier, L., Tobe, S.W., Contemporary use of beta-blocker: clinical relevance of subclassification. Can J Cardiol 30 (2014), S9–S15.
37. 37 Flynn, J.T., Newburger, J.W., Daniels, S.R., et al. A randomized, placebo-controlled trial of amlodipine in children with hypertension. J Pediatr 145 (2004), 353–359.
38. 38 Trachtman, H., Frank, R., Mahan, J.D., et al. Clinical trial of extended-release felodipine in pediatric essential hypertension. Pediatr Nephrol 18 (2003), 548–553.
39. 39 Sorof, J.M., Cargo, P., Graepel, J., et al. B-blocker/thiazide combination for treatment of hypertensive children: a randomized double-blind, placebo-controlled trial. Pediatr Nephrol 17 (2002), 345–350.
40. 40 Chaturvedi, S., Lipszyc, D.H., Licht, C., Craig, J.C., Parekh, R., Pharmacological interventions for hypertension in children. Cochrane Database Syst Rev, 2014, CD008117.
41. 41 Simonetti, G.D., Rizzi, M., Donadini, R., Bianchetti, M.G., Effects of antihypertensive drugs on blood pressure and proteinuria in childhood. J Hypertens 25 (2007), 2370–2376.
42. 42 Juhola, J., Magnussen, C.G., Berenson, G.S., et al. Combined effects of child and adult elevated blood pressure on subclinical atherosclerosis: the International Childhood Cardiovascular Cohort Consortium. Circulation 128 (2013), 217–224.
43. 43 Sun, S.S., Grave, G.D., Siervogel, R.M., et al. Systolic blood pressure in childhood predicts hypertension and metabolic syndrome later in life. Pediatrics 119 (2007), 237–246.
44. 44 Theodore, R.F., Broadbent, J., Nagin, D., et al. Childhood to early-midlife systolic blood pressure trajectories: early-life predictors, effect modifiers, and adult cardiovascular outcomes. Hypertension 66 (2015), 1108–1115.
45. 45 Tirosh, A., Afek, A., Rudich, A., et al. Progression of normotensive adolescents to hypertensive adults: a study of 26980 teenagers. Hypertension 56 (2010), 203–209.
46. 46 Seeman, T., Dostalek, L., Gilik, J., Control of hypertension in treated children and its association with target organ damage. Am J Hypertens 25 (2012), 389–395.
47. 47 Seeman, T., Gilik, J., Vondrak, K., et al. Regression of left-ventricular hypertrophy in children and adolescents with hypertension during Ramipril monotherapy. Am J Hypertens 20 (2007), 990–996.
48. 48 Woroniecki, R.P., Flynn, J.T., How are hypertensive children evaluated and managed? A survey of North American pediatric nephrologists. Pediatr Nephrol 20 (2005), 791–797.
49. 49 Leung, A.A., Daskalopoulou, S.S., Dasgupta, K., for Hypertension Canada. Hypertension Canada's 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults. Can J Cardiol 33 (2017), 557–576.